Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23657487 | 0.87 | RAB9A (0.62) | TRPV1HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL679895 | 0.82 | PDPK1 (0.57) | HDAC3HDAC11HDAC8HDAC6HDAC4 | |
| SCHEMBL3875835 | 0.80 | TRPV1 (0.76) | TRPV1 | |
| SCHEMBL7303163 | 0.78 | HDAC3 (0.86) | TRPV1HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL16378731 | 0.78 | RAB9A (0.73) | — | |
| SCHEMBL5934260 | 0.78 | TRPV1 (0.68) | TRPV1HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL28835090 | 0.78 | AGER (0.58) | HDAC3HDAC11HDAC8HDAC6HDAC4 | |
| SCHEMBL13212115 | 0.76 | KMT2A (0.76) | — | |
| SCHEMBL3875270 | 0.76 | TRPV1 (0.61) | TRPV1HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL8117503 | 0.76 | CYP17A1 (0.57) | HDAC3HDAC11HDAC8HDAC6HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673342-A2 | AMIDES THAT INHIBIT VANILLOID RECEPROT SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2006-06-28 | — | — | EP | claimed |
| US-7037927-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-05-02 | — | — | US | claimed |
| WO-2005040121-A2 | AMIDES THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2005-05-06 | — | — | WO | claimed |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-04-21 | — | — | US | claimed |
| US-7595332-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | ABBOTT LABORATORIES (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1673342-A2 | AMIDES THAT INHIBIT VANILLOID RECEPROT SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060122231-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | ABBVIE INC. | 2006-06-08 | — | — | US | disclosed |
| US-7037927-B2 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2005040121-A2 | AMIDES THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122231-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) | TRPV1, OPRL1, AVPR2 | TRPV1 1/4885HDAC3 1833/4885HDAC11 935/4885 |
| US-20050085512-A1 | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, OPRL1, AVPR1A | TRPV1 1/4885HDAC3 1725/4885HDAC11 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.